Corvus Pharmaceuticals (NASDAQ:CRVS) Issues Earnings Results, Misses Estimates By $0.02 EPS

Corvus Pharmaceuticals (NASDAQ:CRVS) issued its quarterly earnings results on Thursday. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.02), Bloomberg Earnings reports.

CRVS stock traded down $0.04 during midday trading on Friday, reaching $3.79. 316,121 shares of the company were exchanged, compared to its average volume of 307,385. The company has a current ratio of 12.39, a quick ratio of 12.39 and a debt-to-equity ratio of 0.03. Corvus Pharmaceuticals has a 1-year low of $3.22 and a 1-year high of $11.23. The company’s 50-day moving average price is $4.67.

CRVS has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 15th. Roth Capital initiated coverage on shares of Corvus Pharmaceuticals in a research note on Wednesday, May 29th. They issued a “buy” rating and a $6.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $9.19.

In other Corvus Pharmaceuticals news, major shareholder Holdings A/S Novo sold 1,400,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $4.00, for a total transaction of $5,600,000.00. Following the sale, the insider now owns 4,380,800 shares of the company’s stock, valued at $17,523,200. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Richard A. Md Miller acquired 15,212 shares of the business’s stock in a transaction on Tuesday, June 11th. The shares were bought at an average cost of $3.49 per share, for a total transaction of $53,089.88. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 730,534 shares of company stock worth $2,695,804. 40.40% of the stock is owned by corporate insiders.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

Featured Article: What is dollar cost averaging (DCA)?

Earnings History for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with's FREE daily email newsletter.